Gabriella Hartman

Ms. Gabriella Hartman

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GHGabriella Hartman
Gabriella Hartman
NLNathan A. Lambert-Cheatham
Nathan A. Lambert-Cheatham
MKMark Kelley
Mark Kelley
Timothy CorsonTimothy Corson
Timothy Corson
Proliferative diabetic retinopathy (PDR), neovascular age-related macular degeneration (nvAMD), retinopathy of prematurity (ROP) and other eye diseases are characterized by retinal and/or choroidal neovascularization, ultimately causing vision loss in millions of people worldwide. nvAMD and PDR are associated with aging and the number of those affected is expected to increase as the global median age and life expectancy continue to rise. With this increase in prevalence, the development of novel, orally bioavailable therapies for neovascular eye diseases that target multiple pathways is critical, since current anti-vascular endothelial growth factor (VEGF) treatments, delivered by intravitreal injection, are accompanied with tachyphylaxis, a high treatment burden and risk of complications. One potential target is apurinic/apyrimidinic endonuclease 1/reduction-oxidation factor 1 (APE1/Ref-1). The multifunctional protein APE1/Ref-1 may be targeted via inhibitors of its redox-regulating transcription factor activation activity to modulate angiogenesis, inflammation, oxidative stress response and cell cycle in neovascular eye disease; these inhibitors also have neuroprotective effects in other tissues. An APE1/Ref-1 small molecule inhibitor is already in clinical trials for cancer, PDR and diabetic macular edema. Efforts to develop further inhibitors are underway. APE1/Ref-1 is a novel candidate for therapeutically targeting neovascular eye diseases and alleviating the burden associated with anti-VEGF intravitreal injections.

3 January 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
SASurabhi D. Abhyankar
Surabhi D. Abhyankar
QLQianyi Luo
Qianyi Luo
GHGabriella Hartman
Gabriella Hartman
NMNeha Mahajan
Neha Mahajan
TCTimothy W. Corson
Timothy W. Corson
ABAshay Bhatwadekar
Ashay Bhatwadekar
INTRODUCTION: Late‐onset Alzheimer's Disease (LOAD) is the predominant form of Alzheimer's disease (AD), and apolipoprotein E ( APOE ) ε4 is a strong genetic risk factor for LOAD. As an integral part of the central nervous system, the retina displays a variety of abnormalities in LOAD. Our study is focused on age‐dependent retinal impairments in humanized APOE4 ‐knock‐in (KI) and APOE3 ‐KI mice developed by the Model Organism Development and Evaluation for Late‐Onset Alzheimer's Disease (MODEL‐AD) consortium. METHODS: All the experiments were performed on 52‐ to 57‐week‐old mice. The retina was assessed by optical coherence tomography, fundoscopy, fluorescein angiography, electroretinography, optomotor response, gliosis, and neuroinflammation. mRNA sequencing was performed to find molecular pathways. RESULTS: APOE4 ‐KI mice showed impaired retinal structure, vasculature, function, vision, increased gliosis and neuroinflammation, and downregulation of synaptogenesis. DISCUSSION: The APOE ε4 allele is associated with increased susceptibility to retinal degeneration compared to the APOE ε3 allele. Highlights: Apolipoprotein E (APOE) 4 mice exhibit structural and functional deficits of the retina. The retinal defects in APOE4 mice are attributed to increased neuroinflammation. APOE4 mice show a unique retinal transcriptome, yet with key brain similarities. The retina offers a non‐invasive biomarker for the detection and monitoring of Alzheimer's disease.

4 February 2025 in The FASEB Journal
Verified
Journal Article
Open access
GHGabriella Hartman
Gabriella Hartman
AMAnbukkarasi Muniyandi
Anbukkarasi Muniyandi
KSKamakshi Sishtla
Kamakshi Sishtla
EKEyram K. Kpenu
Eyram K. Kpenu
WMWILLIAM PHILLIP MILLER
WILLIAM PHILLIP MILLER
Timothy CorsonTimothy Corson
Timothy Corson
Retinal neovascularization impairs visual function and is a hallmark of several neovascular eye diseases, including retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (PDR). Current treatments include intravitreal injections of anti‐vascular endothelial growth factor (VEGF) biologics, but these therapeutics are often accompanied by high treatment burden and resistance to therapy. Prior studies indicate that APE1/Ref‐1, a multifunctional protein with both endonuclease (APE1) and redox‐mediated transcriptional regulatory activity (Ref‐1), activates multiple pro‐angiogenic and pro‐inflammatory signaling pathways by chemically reducing key cysteine residues in transcription factors, thereby activating them. Here, we investigated the previously unexplored role of Ref‐1 in retinal neovascularization. We demonstrate that Ref‐1 is highly expressed in endothelial cells in human PDR and in the oxygen‐induced retinopathy (OIR) mouse model of retinal neovascularization. Ref‐1 is also highly expressed in microglia and astrocytes in OIR. A small molecule Ref‐1 redox inhibitor, APX2009, decreased retinal neovascularization in OIR after systemic delivery. In vitro, hypoxic endothelial cells did not exhibit upregulation of Ref‐1 but rather increased Ref‐1 nuclear localization. APX2009 decreased hypoxic endothelial cell proliferation and HIF‐1α transcriptional activation. Thus, Ref‐1 redox activity may be a novel therapeutic target for the treatment of retinal neovascularization, making APX2009 a promising systemic therapeutic approach for the treatment of vascular retinopathies such as ROP and PDR.

Verified
Journal Article
Open access
PDF file
MMMahmut Mijit
Mahmut Mijit
SLSheng Liu
Sheng Liu
KSKamakshi Sishtla
Kamakshi Sishtla
GHGabriella Hartman
Gabriella Hartman
Jun WanJun Wan
Jun Wan
MKMark Kelley
Mark Kelley
APE1/Ref-1 (apurinic/apyrimidinic endonuclease 1, APE1 or APEX1; redox factor-1, Ref-1) is a dual-functional enzyme with crucial roles in DNA repair, reduction/oxidation (redox) signaling, and RNA processing and metabolism. The redox function of Ref-1 regulates several transcription factors, such as NF-κB, STAT3, HIF-1α, and others, which have been implicated in multiple human diseases, including ocular angiogenesis, inflammation, and multiple cancers. To better understand how APE1 influences these disease processes, we investigated the effects of APEX1 knockdown (KD) on gene expression in human retinal endothelial cells. This abolishes both DNA repair and redox signaling functions, as well as RNA interactions. Using RNA-seq analysis, we identified the crucial signaling pathways affected following APEX1 KD, with subsequent validation by qRT-PCR. Gene expression data revealed that multiple genes involved in DNA base excision repair, other DNA repair pathways, purine or pyrimidine metabolism signaling, and histidine/one carbon metabolism pathways were downregulated by APEX1 KD. This is in contrast with the alteration of pathways by APEX1 KD in human cancer lines, such as pancreatic ductal adenocarcinoma, lung, HeLa, and malignant peripheral nerve sheath tumors. These results highlight the unique role of APE1/Ref-1 and the clinical therapeutic potential of targeting APE1 and pathways regulated by APE1 in the eye. These findings provide novel avenues for ocular neovascularization treatment.

Verified
Journal Article
Open access
PDF file
BPBomina Park
Bomina Park
SPSHEIK PRAN BABU SARDAR PASHA
SHEIK PRAN BABU SARDAR PASHA
KSKamakshi Sishtla
Kamakshi Sishtla
GHGabriella Hartman
Gabriella Hartman
XQXiaoping Qi
Xiaoping Qi
Timothy CorsonTimothy Corson
Timothy Corson
Neovascular or “wet” age-related macular degeneration (nAMD) is a leading cause of blindness among older adults. Choroidal neovascularization (CNV) is a major pathological feature of nAMD, in which abnormal new blood vessel growth from the choroid leads to irreversible vision loss. There is a critical need to develop novel therapeutic strategies to address limitations of the current anti-vascular endothelial growth factor biologics. Previously, we identified soluble epoxide hydrolase (sEH) as a possible therapeutic target for CNV through a forward chemical genetic approach. The purpose of this study was to validate sEH as a target by examining retinal expression of sEH protein and mRNA by immunohistochemistry and RNAscope in situ hybridization, respectively, and to assess the efficacy of an adeno-associated virus (AAV) vector designed to knock down the sEH gene, Ephx2, in the murine laser-induced (L-) CNV model. nAMD patient postmortem eye tissue and murine L-CNV showed overexpression of sEH in photoreceptors and retinal pigment epithelial cells. Ephx2 knockdown significantly reduced CNV and normalized mRNA expression levels of CNV-related inflammatory markers. Thus, this study further establishes sEH as a promising therapeutic target against CNV associated with nAMD.

1 August 2025 in bioRxiv
Verified
Preprint
Open access
SASurabhi D. Abhyankar
Surabhi D. Abhyankar
QLQianyi Luo
Qianyi Luo
GHGabriella Hartman
Gabriella Hartman
NMNeha Mahajan
Neha Mahajan
Timothy CorsonTimothy Corson
Timothy Corson
ABAshay Bhatwadekar
Ashay Bhatwadekar
The APOE genotype influences metabolic and neurodegenerative outcomes, with APOE4 carriers at higher risk for Alzheimer’s disease (AD) and metabolic dysfunction. This study examines how long-term dietary interventions affect systemic metabolism, retinal structure/ function in APOE3 -knock-in (KI, neutral for AD) and APOE4 -KI mice. Humanized APOE3 and APOE4 -KI mice received either a control diet (CD) or a Western diet (WD) for 2, 6, or 12 months. Body weight, glucose metabolism, lipid profiles, retinal structure, function, vasculature, visual performance, and inflammatory markers were analyzed. WD induced early glucose intolerance in APOE4 mice (2 months); APOE3 mice showed impairment only after prolonged exposure (6-12 months). Notably, WD-fed APOE3 mice exhibited more pronounced hyperlipidemia than APOE4 mice. APOE4 CD mice displayed early retinal thinning (6 months), while APOE4 WD mice initially exhibited retinal swelling, followed by degeneration (12 months). WD exacerbated retinal vascular dysfunction in APOE4 mice, with increased tortuosity and reduced vascular area. Elevated Il1b expression in WD-fed APOE4 mice confirmed inflammation-associated retinal dysfunction. APOE4 mice showed heightened vulnerability to diet, with WD worsening metabolic, retinal, and vascular impairments. While CD improved glucose metabolism, it did not prevent retinal dysfunction. These findings underscore genotype-specific dietary strategies to mitigate APOE4 -associated risks.